ANI Pharmaceuticals Financial Statements (ANIP)
|
|
|
|
Report date
|
|
|
15.03.2022 |
09.03.2023 |
29.02.2024 |
28.02.2025 |
27.02.2026 |
|
08.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
216.1 |
316.4 |
486.8 |
614.4 |
883.4 |
|
923.7 |
|
Operating Income, bln rub |
|
|
-39.8 |
-35.3 |
47.0 |
0.584 |
81.2 |
|
123.6 |
|
EBITDA, bln rub |
? |
|
3.12 |
25.0 |
106.6 |
63.1 |
207.3 |
|
237.0 |
|
Net profit, bln rub |
? |
|
-42.6 |
-47.9 |
18.8 |
-18.5 |
78.3 |
|
89.7 |
|
|
OCF, bln rub |
? |
|
3.32 |
-31.2 |
119.0 |
64.0 |
185.2 |
|
208.6 |
|
CAPEX, bln rub |
? |
|
23.6 |
16.5 |
18.5 |
17.0 |
13.8 |
|
43.0 |
|
FCF, bln rub |
? |
|
-20.3 |
-47.7 |
100.4 |
47.1 |
171.4 |
|
165.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
155.3 |
212.9 |
258.3 |
363.6 |
369.4 |
|
485.5 |
|
Cost of production, bln rub |
|
|
100.6 |
138.8 |
181.5 |
250.2 |
432.7 |
|
314.6 |
|
R&D, bln rub |
|
|
11.4 |
22.3 |
34.3 |
44.6 |
51.7 |
|
51.7 |
|
Interest expenses, bln rub |
|
|
11.9 |
28.1 |
26.9 |
17.6 |
20.1 |
|
39.6 |
|
|
Assets, bln rub |
|
|
771.6 |
760.1 |
904.4 |
1 284 |
1 440 |
|
1 422 |
|
Net Assets, bln rub |
? |
|
358.7 |
338.5 |
457.6 |
428.5 |
540.7 |
|
562.3 |
|
Debt, bln rub |
|
|
287.4 |
286.5 |
285.7 |
624.1 |
325.2 |
|
327.8 |
|
Cash, bln rub |
|
|
100.3 |
48.2 |
221.1 |
151.2 |
285.6 |
|
311.2 |
|
Net debt, bln rub |
|
|
187.1 |
238.3 |
64.5 |
472.9 |
39.6 |
|
16.6 |
|
|
Ordinary share price, rub |
|
|
46.1 |
|
|
55.3 |
78.9 |
|
76.9 |
|
Number of ordinary shares, mln |
|
|
12.6 |
16.3 |
18.0 |
19.3 |
20.1 |
|
20.9 |
|
|
Market cap, bln rub |
|
|
580 |
0 |
0 |
1 068 |
1 583 |
|
1 608 |
|
EV, bln rub |
? |
|
767 |
238 |
65 |
1 541 |
1 623 |
|
1 625 |
|
Book value, bln rub |
|
|
37 |
59 |
220 |
-173 |
-1 |
|
33 |
|
|
EPS, rub |
? |
|
-3.38 |
-2.95 |
1.04 |
-0.96 |
3.91 |
|
4.29 |
|
FCF/share, rub |
|
|
-1.61 |
-2.93 |
5.58 |
2.44 |
8.55 |
|
7.92 |
|
BV/share, rub |
|
|
2.92 |
3.61 |
12.2 |
-8.97 |
-0.06 |
|
1.56 |
|
|
EBITDA margin, % |
? |
|
1.44% |
7.91% |
21.9% |
10.3% |
23.5% |
|
25.7% |
|
Net margin, % |
? |
|
-19.7% |
-15.1% |
3.86% |
-3.01% |
8.87% |
|
9.71% |
|
FCF yield, % |
? |
|
-3.50% |
|
|
4.41% |
10.8% |
|
10.3% |
|
ROE, % |
? |
|
-11.9% |
-14.1% |
4.10% |
-4.32% |
14.5% |
|
15.9% |
|
ROA, % |
? |
|
-5.52% |
-6.30% |
2.08% |
-1.44% |
5.44% |
|
6.31% |
|
|
P/E |
? |
|
-13.6 |
0.00 |
0.00 |
-57.7 |
20.2 |
|
17.9 |
|
P/FCF |
|
|
-28.6 |
0.00 |
0.00 |
22.7 |
9.24 |
|
9.71 |
|
P/S |
? |
|
2.69 |
0.00 |
0.00 |
1.74 |
1.79 |
|
1.74 |
|
P/BV |
? |
|
15.8 |
0.00 |
0.00 |
-6.16 |
-1 235 |
|
49.2 |
|
EV/EBITDA |
? |
|
246.3 |
9.52 |
0.61 |
24.4 |
7.83 |
|
6.86 |
|
Debt/EBITDA |
|
|
60.0 |
9.52 |
0.61 |
7.49 |
0.19 |
|
0.07 |
|
|
R&D/CAPEX, % |
|
|
48.1% |
135.6% |
185.2% |
263.0% |
373.4% |
|
120.2% |
|
|
CAPEX/Revenue, % |
|
|
10.9% |
5.20% |
3.80% |
2.76% |
1.57% |
|
4.66% |
|
| ANI Pharmaceuticals shareholders |
